<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03203915</url>
  </required_header>
  <id_info>
    <org_study_id>81946-4</org_study_id>
    <nct_id>NCT03203915</nct_id>
  </id_info>
  <brief_title>Metabolic Response to Chardonnay Grape Marc Powder</brief_title>
  <official_title>Metabolic Response to Chardonnay Grape Marc Powder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>USDA, Western Human Nutrition Research Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sonomaceuticals LLC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>USDA, Western Human Nutrition Research Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if the addition of chardonnay grape marc (also called pomace) powder enriched
      with grape seed extract to the diet will result in reducing blood levels of cholesterol or
      triglycerides.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Previous research on grape seed nutritional properties has predominantly been confined to
      grape seed extracts (GSE) containing only soluble components. In animal models, GSE has been
      shown to prevent increases in blood pressure, blood cholesterol, and insulin resistance. In
      humans, there have been improvements in blood pressure, however no significant effect on
      blood cholesterol levels. Whole milled grape marc flours deliver more dietary complexity than
      seed extracts alone. In addition to the extractable and non-extractable polyphenols, flour
      offers dietary fiber, minerals, sterols and polyunsaturated fats. Grape marc flour is
      currently used as a food ingredient that is incorporated into various baked goods. However,
      to obtain good control of the dose level, the product will be provided in capsule form for
      this study. For reference, a ½ cup of of a high polyphenol food such as blueberries, contains
      about 325 milligrams of polyphenols, thus even with the higher dose, participants will be
      receiving an amount of polyphenols that is less than ¼ cup of blueberries. The grape marc
      powder is prepared in a facility that is certified for producing food-grade products, and the
      nutritional composition and safety of the product will be thoroughly evaluated before we
      begin the study. The objective of the current study is to determine if this chardonnay grape
      marc powder enriched with grape seed extract supplementation has beneficial impacts on the
      human blood lipid profile and to correlate gut biome changes to human metabolism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">June 28, 2019</completion_date>
  <primary_completion_date type="Actual">June 28, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in lipid profile</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Fasting triglyceride concentrations, LDL cholesterol, HDL cholesterol, non-HDL cholesterol will be measured in serum</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in fecal microbiome profile</measure>
    <time_frame>Weeks 1, 4, 10, 16</time_frame>
    <description>Gut microbiota community profile will be determined by 6M read metagenomic gene sequencing from stool samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in gut fermentation profile</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Hydrogen and methane gas (parts per million) will be measured simultaneously in breath to assess gut fermentation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in inflammatory markers</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Immunological markers such as: tumor necrosis factor-α, Interleukin-β, Interleukin-6, Interleukin-1B, Interleukin-10, Interleukin-18, Interleukin-1a, Intercellular Adhesion Molecule 1, vascular cell adhesion molecule 1, C-reactive protein, Serum amyloid A, neopterin, myeloperoxidase, eotaxin, Interferon gamma-induced protein 10, Myeloid dendritic cell, monocyte chemoattractant protein 1, Matrix metalloproteinase-1, Matrix metalloproteinase-3, Matrix metalloproteinase-9</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in endothelial function measurement and blood pressure</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Blood pressure will be measured each test day. Endothelial function will be measured once per day using peripheral arterial tone (PAT) signal technology. Endothelial function is expressed as a Reactive Hyperemia Index (RHI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in metabolomic profile</measure>
    <time_frame>Weeks 1, 4, 10, 16</time_frame>
    <description>Fecal bile acids, plasma bile acids, fecal and plasma short-chain fatty acids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in cognitive function</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Executive function will be assessed using Cambridge Neuropsychological Test Automated Battery (CANTAB) and Autonomic Nervous System Output.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in glucose metabolism</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Glucose and insulin measures at fasting and after challenge meal. this includes assessing insulin resistance and sensitivity indexes</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in appetite hormones</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Leptin, Ghrelin, Peptide YY 3-36, Glucagon-like peptide-1 at fasting and postprandial</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in body composition and energy expenditure</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Body composition by Dual energy X-ray Absorptiometry scan (radiologic exposure), body weight, waist and hip circumference, indirect calorimetry measured each visit</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in self-report of hunger and mood</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Subjective rating measures using a visual analog scale</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in NMR lipid particle profile</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>cholesterol species (e.g. VLDL, IDL, LDL, etc) identified and their particle sizes (e.g. small, medium, large) identified at fasting and 3hr postprandial</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in oxidized LDL</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>oxidized LDL measured at fasting and 1, 2, 3 hrs postprandial</description>
  </other_outcome>
  <other_outcome>
    <measure>Changes in apolipoprotein profile</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>Apo CIII, Apo B, Apo AI, Apo E measured at fasting and postprandial</description>
  </other_outcome>
  <other_outcome>
    <measure>General health</measure>
    <time_frame>Weeks 4, 10, 16</time_frame>
    <description>General well being via questionnaire, comprehensive metabolic panel, fatty liver index</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Dyslipidemia</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of treatments:
A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose C: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of treatments:
A: Chardonnay grape marc powder high polyphenol dose C: Placebo B: Chardonnay grape marc powder low polyphenol dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of treatments:
B: Chardonnay grape marc powder low polyphenol dose C: Placebo A: Chardonnay grape marc powder high polyphenol dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of treatments:
B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose C: Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of treatments:
C: Placebo A: Chardonnay grape marc powder high polyphenol dose B: Chardonnay grape marc powder low polyphenol dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Order of treatments:
C: Placebo B: Chardonnay grape marc powder low polyphenol dose A: Chardonnay grape marc powder high polyphenol dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chardonnay grape marc marc high polyphenol dose (120mg)</intervention_name>
    <description>3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chardonnay grape marc powder low polyphenol dose (75mg)</intervention_name>
    <description>3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo (0mg)</intervention_name>
    <description>3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols</description>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  BMI ≥ 25 and &lt; 40 kg/m2

          -  Dyslipidemia as defined as (any one or all of the following values):

          -  Total cholesterol &gt; 190 mg/dL but &lt; 240 mg/dL

          -  LDL-cholesterol &gt; 130 mg/dL but &lt; 160 mg/dL

          -  HDL-cholesterol &lt; 40 mg/dL (men)/&lt;50 mg/dL (women)

          -  Fasting triglycerides &gt; 150 mg/dL but &lt; 300 mg/dL

        Exclusion Criteria:

          -  Renal, cardiovascular, gastrointestinal or hepatic disease, by medical history

          -  History of a previous cardiovascular event

          -  Diagnosis of type 2 diabetes

          -  Pregnancy or lactation

          -  Use of tobacco

          -  Food sensitivities or allergies to the foods or components of foods provided in the
             standard meals including gluten, dairy, egg, soy, nuts, or seafood

          -  Use of herbal or plant-based supplements; omega-3 fatty acids, and fish oils in the
             past 3-6 months, and unwilling to discontinue use while participating in the study.

          -  Use of lipid-lowering, glucose-lowering, anti-hypertensive, or weight loss medications

          -  Use of antibiotics in the last three months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy L Keim, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>USDA ARS</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Western Human Nutrition Research Center</name>
      <address>
        <city>Davis</city>
        <state>California</state>
        <zip>95616</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 29, 2017</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cholesterol</keyword>
  <keyword>triglyceride</keyword>
  <keyword>grape seed extract</keyword>
  <keyword>chardonnay marc powder</keyword>
  <keyword>polyphenol</keyword>
  <keyword>gut microbiome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

